This past fall, the National Institutes of Health, the Food and Drug Administration and other partners launched the Bespoke Gene Therapy Consortium in an effort to leverage adeno-associated viruses as vectors to treat rare diseases. The initiative seeks to streamline research to clinical use, driving efficiencies into the traditional research and development process. FDA leader Peter Marks and NIH’s P.J. Brooks discuss the consortium’s work and how it aims to help people with rare diseases.
HealthCast
Season 2
Episode 39
21m listen
Gene Therapy is Fighting Rare Diseases in FDA, NIH Program
![HealthCast: Gene Therapy is Fighting Rare Diseases in FDA, NIH Program](https://govciomedia.com/wp-content/uploads/2023/12/1000x650_HealthCast_Gene_Therapy_Consortium_v2.jpeg?fit=max&auto=format&cs=adobergb1998&auto=compress)
The technique aims to treat some diseases by gene replacement.
![HealthCast: Gene Therapy is Fighting Rare Diseases in FDA, NIH Program](https://govciomedia.com/wp-content/uploads/2023/12/1000x650_HealthCast_Gene_Therapy_Consortium_v2.jpeg?fit=max&auto=format&cs=adobergb1998&auto=compress)
-
Peter Marks Director CBER, FDA
-
P.J. Brooks Deputy Director, Office of Rare Diseases Research NCATS, NIH
Related Content
-
Inside VA’s Lighthouse for App Development
Andrew Fichter discusses how Lighthouse is serving veterans and why it is necessary for modernization of veterans services.
24m listen -
Exploring the Link Between Climate Change and Public Health
Dr. John Balbus, Climate Change and Health Equity Director, HHS
35m listen -
Transparency Around Cyber Attacks Can Prevent Future Ones
Cybersecurity leader Suzanne Spaulding said implementing radical transparency in cybersecurity can benefit federal agencies and national security overall.
21m listen -
Emerging Tech Parallels Emerging Risks for VA Health Care
Amber Pearson, Executive Director, Information Security Policy and Strategy, VA
20m listen